Comparing the Efficacy of Antiosteoporotic Drugs in Preventing Periprosthetic Bone Loss Following Total Hip Arthroplasty: A Systematic Review and Bayesian Network Meta-Analysis

Abstract

Background: Periprosthetic bone loss is a well-known phenomenon following total hip arthroplasty (THA). However, the choice of drugs for prevention remains controversial. Therefore, the aim of this study was to determine the best drug to treat periprosthetic bone loss by comparing changes in bone mineral density (BMD) at different times after THA.

Methods: A comprehensive search of five databases and two clinical trial registration platforms was undertaken from their inception through to August 31, 2023 to identify eligible randomized controlled trials. A Bayesian network meta-analysis (NMA) was carried out for calculating the standardized mean difference (SMD) and the surface under cumulative ranking curve (SUCRA) of the BMD in calcar (Gruen zone 7) at 6 months, 12 months, and 24 months and over.

Results: Twenty-nine trials involving 1427 patients and 10 different interventions were included. The results demonstrated that at 6 months, denosumab had the highest ranking (SUCRA = 0.90), followed by alendronate (SUCRA = 0.76), and zoledronate (SUCRA = 0.73). At 12 months, clodronate ranked highest (SUCRA = 0.96), followed by denosumab (SUCRA = 0.84) and teriparatide (SUCRA = 0.82). For interventions with a duration of 24 months and over, denosumab had the highest SUCRA value (SUCRA = 0.96), followed by raloxifene (SUCRA = 0.90) and zoledronate (SUCRA = 0.75).

Conclusion: Investigating the existing body of evidence revealed that denosumab demonstrates potential as an intervention of superior efficacy at the three specifically examined time points. However, it remains crucial to conduct further research to confirm these findings and determine the most effective treatment strategy.

Keywords

antiosteoporotic drugs / bone loss / network Meta-analysis / THA

References

[1] Rosemont I. American joint replacement registry (AJRR): 2023 annual report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS); 2023.

[2] Bobyn JD, Mortimer ES, Glassman AH, et al. Producing and avoiding stress shielding. Laboratory and clinical observations of noncemented total hip arthroplasty. Clin Orthop Relat Res. 1992;274: 79–96.

[3] Gruen TA, McNeice GM, Amstutz HC. “Modes of failure” of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141: 17–27.

[4] Nyström A, Kiritopoulos D, Mallmin H, Lazarinis S. Continuous periprosthetic bone loss but preserved stability for a collum femoris-preserving stem: follow-up of a prospective cohort study of 21 patients with dualenergy X-ray absorptiometry and radiostereometric analysis with minimum 8 years of follow-up. Acta Orthop. 2022; 93: 206–211.

[5] Shi J, Liang G, Huang R, Liao L, Qin D. Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis. J Orthop Surg Res. 2018; 13: 225.

[6] Chen X, Shen Y, Ye C, Mumingjiang Y, Lu J, Yu Y. Prophylactic efficacy on periprosthetic bone loss in calcar region after total hip arthroplasty of antiosteoporotic drugs: a network meta-analysis of randomised controlled studies. Postgrad Med J. 2021; 97: 150–155.

[7] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162: 777–784.

[8] Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020; 37: 387.

[9] Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012; 28: 138–144.

[10] JPT Higgins, J Thomas, J Chandler, M Cumpston, T Li, MJ Page, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.

[11] Rücker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods. 2017; 8: 392–403.

[12] McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012; 22: 276–282.

[13] GitHub. gertvv/gemtc: GeMTC R package: model generation for network meta-analysis. https://github.com/gertvv/gemtc Accessed August 25, 2023.

[14] Flemyng E, Dwan K, Moore TH, et al. Risk of bias 2 in cochrane reviews: a phased approach for the introduction of new methodology. Cochrane Database Syst Rev. 2020; 10: ED000148.

[15] Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, del Giovane C, Egger M, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020; 17: e1003082.

[16] Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020; 16: e1080.

[17] Iwamoto N, Inaba Y, Kobayashi N, Ishida T, Yukizawa Y, Saito T. A comparison of the effects of alendronate and Alfacalcidol on Bone mineral density around the femoral implant and in the lumbar spine after Total hip arthroplasty. J Bone Joint Surg. 2011; 93: 1203–1209.

[18] Aro E, Moritz N, Mattila K, Aro HT. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: a randomized placebo-controlled trial of women undergoing total hip arthroplasty. J Biomech. 2018; 75: 35–45.

[19] Nishioka T, Yagi S, Mitsuhashi T, Miyamoto M, Tamura T, Kobayashi T, et al. Alendronate inhibits periprosthetic bone loss around uncemented femoral components. J Bone Miner Metab. 2007; 25: 179–183.

[20] Arabmotlagh M, Rittmeister M, Hennigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J Orthop Res. 2006; 24: 1336–1341.

[21] Tapaninen TS, Venesmaa PK, Jurvelin JS, Miettinen HJA, Kröger HPJ. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty—a 5-year follow-up of 16 patients. Scand J Surg. 2010; 99: 32–37.

[22] Venesmaa PK, Kröger HPJ, Miettinen HJA, Jurvelin JS, Suomalainen OT, Alhava EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study. J Bone Miner Res. 2001; 16: 2126–2131.

[23] Huang T-W, Wang C-J, Shih H-N, Chang Y, Huang KC, Peng KT, et al. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. BMC Musculoskelet Disord. 2017; 18: 209.

[24] Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res. 2009; 27: 183–188.

[25] Yamaguchi K, Masuhara K, Yamasaki S, Nakai T, Fuji T. Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty. Bone. 2003; 33: 144–149.

[26] Trevisan C, Ortolani S, Romano P, Isaia G, Agnese L, Dallari D, et al. Decreased periprosthetic bone loss in patients treated with clodronate: a 1-year randomized controlled study. Calcif Tissue Int. 2010; 86: 436–446.

[27] Finnilä S, Löyttyniemi E, Aro HT. Denosumab in cementless total hip arthroplasty: multivariate reanalysis of 3D femoral stem migration and the influence on outliers. JBMR Plus. 2022; 6: e10588.

[28] Nakura N, Hirakawa K, Takayanagi S, Mihara M. Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty. J Bone Miner Metab. 2023; 41: 239–247.

[29] Fokter SK, Komadina R, Repše-Fokter A. Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wien Klin Wochenschr. 2006; 118: 23–28.

[30] Morita A, Kobayashi N, Choe H, Ike H, Tezuka T, Higashihira S, et al. Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial. J Orthop Surg Res. 2020; 15: 17.

[31] Scott DF, Woltz JN, Smith RR. Effect of zoledronic acid on reducing femoral Bone mineral density loss following total hip arthroplasty. J Arthroplasty. 2013; 28: 671–675.

[32] Yamaguchi K, Masuhara K, Yamasaki S, Fuji T, Seino Y. Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty. Bone. 2004; 35: 217–223.

[33] Zhou W, Liu Y, Guo X, Yang H, Xu Y, Geng D. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int. 2019; 30: 1581–1589.

[34] Yukizawa Y, Inaba Y, Kobayashi N, Choe H, Kubota S, Saito T. Efficacy of alendronate for the prevention of Bone loss in calcar region following total hip arthroplasty. J Arthroplasty. 2017; 32: 2176–2180.

[35] Yamaguchi K, Masuhara K, Yamasaki S, Fuji T. Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty. J Orthop Sci. 2005; 10: 32–36.

[36] Fokter SK, Komadina R, Repse-Fokter A, et al. Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty. Int Orthop. 2005; 29: 362–367.

[37] Gong L, Zhang Y, Yang N, Qian HJ, Zhang LK, Tan MS. Raloxifene prevents early periprosthetic bone loss for postmenopausal women after uncemented total hip arthroplasty: a randomized placebo-controlled clinical trial. Orthop Surg. 2020; 12: 1074–1083.

[38] Nagoya S, Tateda K, Okazaki S, Kosukegawa I, Shimizu J, Yamashita T. Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty. Eur J Orthop Surg Traumatol. 2018; 28: 1601–1607.

[39] Yamasaki S, Masuhara K, Yamaguchi K, Nakai T, Fuji T, Seino Y. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporos Int. 2007; 18: 1009–1015.

[40] Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T. Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty–a randomized controlled trial. J Arthroplasty. 2016; 31: 333–338.

[41] Sköldenberg OG, Salemyr MO, Bodén HS, Ahl TE, Adolphson PY. The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg. 2011; 93: 1857–1864.

[42] Iwamoto N, Inaba Y, Kobayashi N, Yukizawa Y, Ike H, Ishida T, et al. The effectiveness of mono or combined osteoporosis drug therapy against bone mineral density loss around femoral implants after total hip arthroplasty. J Bone Miner Metab. 2014; 32: 539–544.

[43] Hsu AHS, Yen C-H, Kuo F-C, Wu CT, Huang TW, Cheng JT, et al. Zoledronic acid ameliorates the bone turnover activity and periprosthetic bone preservation in cementless total hip arthroplasty. Pharmaceuticals. 2022; 15: 420.

[44] Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén-Mallmin M, Milbrink J, et al. Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo-controlled clinical trial. J Bone Miner Res. 2020; 35: 239–247.

[45] Kobayashi S, Saito N, Horiuchi H, Iorio R, Takaoka K. Poor bone quality or hip structure as risk factors affecting survival of total-hip arthroplasty. Lancet. 2000; 355: 1499–1504.

[46] Lindahl H. Epidemiology of periprosthetic femur fracture around a total hip arthroplasty. Injury. 2007; 38: 651–654.

[47] Hegde V, Stambough JB, Levine BR, Springer BD. Highlights of the 2022 American joint replacement registry annual report. Arthroplast Today. 2023; 21: 101137.

[48] de Steiger RN, Miller LN, Prosser GH, Graves SE, Davidson DC, Stanford TE. Poor outcome of revised resurfacing hip arthroplasty. Acta Orthop. 2010; 81: 72–76.

[49] Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009; 24: 182–195.

[50] Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med. 2019; 285: 381–394.

[51] Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5: 513–523.

[52] Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs. 2001; 61: 999–1039.

[53] Wang M, Wu Y-F, Girgis CM. Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. JBMR Plus. 2022; 6: e10629.

[54] McCloskey E, Paterson AH, Powles T, Kanis JA. Clodronate. Bone. 2021; 143: 115715.

[55] Reid IR, Green JR, Lyles KW, et al. Zoledronate. Bone. 2020; 137: 115390.

[56] Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016; 101: 3163–3170.

[57] Gwynne Jones DP, Savage RL, Highton J. Alendronate-induced synovitis. J Rheumatol. 2008; 35: 537–538.

[58] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434–1441.

[59] Wang Y-K, Qin S-Q, Ma T, Song W, Jiang RQ, Guo JB, et al. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017; 96: e6970.

[60] Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022; 17: 58.

[61] Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020; 105: dgaa048.

[62] Khalid AB, Slayden AV, Kumpati J, Perry CD, Berryhill SB, Crawford JA, et al. GATA4 represses RANKL in osteoblasts via multiple long-range enhancers to regulate osteoclast differentiation. Bone. 2018; 116: 78–86.

[63] Liu T-C, Hsu C-N, Lee W-C, Wang SW, Huang CC, Lee YT, et al. Denosumab is superior to raloxifene in lowering risks of mortality and ischemic stroke in osteoporotic women. Pharmaceuticals (Basel). 2023; 16: 222.

[64] Li X, Han J, Shi X, Bi Z, Liu J. Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2023; 18: 37.

[65] Liu Y, Xu J-W, Li M-Y, Wu LM, Zeng Y, Shen B. Zoledronic acid for periprosthetic bone mineral density changes in patients with osteoporosis after hip arthroplasty-an updated meta-analysis of six randomized controlled trials. Front Med (Lausanne). 2021; 8: 801282.

[66] Yang L, Kang N, Yang J-C, Su QJ, Liu YZ, Guan L, et al. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis. Eur Rev Med Pharmacol Sci. 2019; 23: 2640–2668.

[67] Christiansen JD, Laursen MB, Ejaz A, Nielsen PT. Bone remodelling of the proximal femur after total hip arthroplasty with 2 different hip implant designs: 15 years follow-up of the thrust plate prosthesis and the Bi-metric stem. Hip Int. 2018; 28: 606–612.

[68] Peitgen DS, Innmann MM, Merle C, Gotterbarm T, Moradi B, Streit MR. Periprosthetic bone mineral density around uncemented titanium stems in the second and third decade after total hip arthroplasty: a DXA study after 12, 17 and 21 years. Calcif Tissue Int. 2018; 103: 372–379.

[69] Lv Z, Zhang J, Liang S, Zhou C, Hu D, Brooks DJ, et al. Comparative study in estrogen-depleted mice identifies skeletal and osteocyte transcriptomic responses to abaloparatide and teriparatide. JCI Insight. 2023; 8: e161932.

[70] Park D, Kim SE, Shin HK, Seo J, Joo JK, Kim C, et al. Comparison of the efficacy of romosozumab and teriparatide for the management of osteoporotic vertebral compression fractures. Neurospine. 2023; 20: 1217–1223.

RIGHTS & PERMISSIONS

2024 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.